C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 2 151.05 INR 0.71% Market Closed
Market Cap: 225B INR
Have any thoughts about
Concord Biotech Ltd?
Write Note

Concord Biotech Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Concord Biotech Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
C
Concord Biotech Ltd
NSE:CONCORDBIO
Short-Term Investments
â‚ą2.7B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Short-Term Investments
â‚ą55.1B
CAGR 3-Years
49%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Short-Term Investments
â‚ą77.9B
CAGR 3-Years
40%
CAGR 5-Years
36%
CAGR 10-Years
18%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Short-Term Investments
â‚ą117.4B
CAGR 3-Years
44%
CAGR 5-Years
21%
CAGR 10-Years
22%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Short-Term Investments
â‚ą3.3B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
6%
M
Mankind Pharma Ltd
NSE:MANKIND
Short-Term Investments
â‚ą30B
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Concord Biotech Ltd
Glance View

Market Cap
225B INR
Industry
Pharmaceuticals

Nestled in the vibrant landscape of the Indian pharmaceutical industry, Concord Biotech Ltd. has woven itself into the intricate fabric of global healthcare solutions. Founded in 2000, the company has carved a niche for itself by becoming a leading manufacturer of fermentation-based biopharmaceutical APIs (Active Pharmaceutical Ingredients). Its core strength lies in developing recombinant APIs and fermentation-based life-saving drugs, establishing a robust pipeline that caters to the therapeutic needs of oncology, immunology, and infectious diseases. Concord Biotech's state-of-the-art manufacturing facilities adhere to stringent international standards, including approvals from USFDA and EUGMP, enabling the company to establish a significant presence in markets across the globe. The company's revenue model thrives on the optimized production of high-demand biotech APIs, synergizing innovation with commercial viability. By partnering with global pharmaceutical giants, Concord Biotech boosts the formulation and development of finished dosage forms, leveraging its cutting-edge research and development capabilities. The firm taps into economies of scale via partnerships and strategic alliances, which allow it to competitively price its offerings while maintaining robust profit margins. Moreover, the company continually invests in expanding its product portfolio and production capacities, ensuring sustainable growth and a strong market position in the ever-evolving pharmaceutical landscape. Through a combination of technological prowess and market insight, Concord Biotech Ltd. paves its path as a cornerstone in the global pharmaceutical supply chain.

CONCORDBIO Intrinsic Value
1 126.37 INR
Overvaluation 48%
Intrinsic Value
Price
C

See Also

What is Concord Biotech Ltd's Short-Term Investments?
Short-Term Investments
2.7B INR

Based on the financial report for Mar 31, 2024, Concord Biotech Ltd's Short-Term Investments amounts to 2.7B INR.

What is Concord Biotech Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 3Y
24%

Over the last year, the Short-Term Investments growth was 60%. The average annual Short-Term Investments growth rates for Concord Biotech Ltd have been 24% over the past three years .

Back to Top